An oral tablet formulation of the GLP-1 receptor agonist diabetes treatment that was previously only available as an injection is preparing to launch in Korea. The drug is Novo Nordisk’s ‘Rybelsus (semaglutide).'

Novo Nordisk has recently applied for the approval of its Rybelsus tablet to the Korean Ministry of Food and Drug Safety (MFDS). With Lilly’s GLP-1 RA Trulicity (dulaglutide) gaining popularity in the diabetes treatment market, the emergence of a tablet formulation with improved convenience may likely trigger market restructuring.

On the 7th, industry sources have said that Novo Nordisk had recently submitted an application for the market approval of its Rybelsus table